Chemistry:NM-2201
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C24H22FNO2 |
| Molar mass | 375.443 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
NM-2201 (also known as CBL-2201 and NA-5F-PIC[1]) is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB1 and CB2 receptors with low nanomolar affinity.[2][3][4][5]
Pharmacology
NM-2201 acts as a full agonist with a binding affinity of 0.332 nM at CB1 and 0.732 nM at CB2 cannabinoid receptors.[6] It has been linked to serious adverse events in users.[7]
Legal status
NM-2201 is specifically banned in Sweden,[8] Germany (Anlage II),[9] and Japan[10] but is also controlled in many other jurisdictions under analogue laws.
On May 30, 2018 the United States Drug Enforcement Administration, Department of Justice published a notice of intent to place NM-2201 and 4 other synthetic cannabinoids in schedule I of the Controlled Substances Act. This notice went into effect on June 29, 2018.[11]
Use
NM-2201 was linked to an incident in December 2015 where 25-30 people in Ocala, FL were taken to hospitals after experiencing seizures.[11]
See also
References
- ↑ Pulver, Benedikt; Fischmann, Svenja; Gallegos, Ana; Christie, Rachel (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis 15 (3): 255–276. doi:10.1002/dta.3403.
- ↑ "CBL-2201. Report on a new designer drug: Napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate". Forensic Science International 257: 209–213. December 2015. doi:10.1016/j.forsciint.2015.08.023. PMID 26386336.
- ↑ "NM-2201". Cayman Chemical. https://www.caymanchem.com/app/template/Product.vm/catalog/15334.
- ↑ "Comprehensive review of the detection methods for synthetic cannabinoids and cathinones". Forensic Toxicology 33 (2): 175–194. 2015. doi:10.1007/s11419-015-0270-0. PMID 26257831.
- ↑ "Synthetic cannabinoids as designer drugs: new representatives of indol-3-carboxylates series and indazole-3-carboxylates as novel group of cannabinoids. Identification and analytical data". Forensic Science International 244: 263–75. November 2014. doi:10.1016/j.forsciint.2014.09.013. PMID 25305529.
- ↑ "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology 34 (2): 329–343. 2016. doi:10.1007/s11419-016-0320-2. PMID 27429655.
- ↑ "black mamba". BMJ Case Reports 2017: bcr–2016–218431. April 2017. doi:10.1136/bcr-2016-218431. PMID 28433979.
- ↑ "Cannabinoider föreslås bli klassade som hälsofarlig vara" (in sv). Folkhälsomyndigheten. http://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2014/november/cannabinoider-foreslas-bli-klassade-som-halsofarlig-vara/.
- ↑ "Gesetz über den Verkehr mit Betäubungsmitteln Anlage II" (in de). Bundesministerium der Justiz und für Verbraucherschutz. https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html.
- ↑ "In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201)". Forensic Toxicology 35 (1): 20–32. January 2017. doi:10.1007/s11419-016-0326-9. PMID 28286577.
- ↑ 11.0 11.1 "2018 - Temporary Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA Into Schedule I" (in en-US). https://www.deadiversion.usdoj.gov/fed_regs/rules/2018/fr0530.htm.
 |  |
